In our study, we found that the mRNA level of MTA1 is higher in breast cancer, as compared with normal tissue through TCGA debase analysis, and the clinical data showed that MTA1 was up-regulated in samples among the clinical stage-III/IV, when compared with samples in stage-I/II (Figure 1M). This evidence concerns the gene MTA1 and breast carcinoma.